This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
There was no observation related to data integrity reported
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Subscribe To Our Newsletter & Stay Updated